Purchasing a pipeline – perils, pitfalls, and priorities in asset acquisition

Checkpoint inhibitors. Genetic therapies. Biomarker therapies. To hear big pharma tell it, we are living in an age of medical wonders.

The problem? In some patients, they make a huge difference. In others, they don’t work at all.

From a bench-science standpoint, that’s fascinating. But if you’re a pharmaceutical executive thinking seriously about pipeline asset acquisition, translating large-molecule science into high-profit marketability is fraught with complexity.

In this White Paper, we will look at new and changing trends in pipeline acquisition, discuss difficulties inherent in the current marketplace, and offer worthwhile perspectives on pitfalls and opportunities based on our experience offering strategic guidance to pharmaceutical companies on a global scale.

Big pharma pipelines are not what they used to be

The majority of new drugs measure their success in increments.

Orphan drugs and tightly targeted MOAs offer the most exciting breakthroughs, but they offer them to smaller and smaller groups of patients. New cancer drugs are launched with great fanfare even when their pivotal studies suggest they offer a scant three months’ improvement over the competition. Small molecules are languishing. Biologics, once heralded as an arena of unbounded promise, are nearing the end of their patent lives, negotiating payments worth millions to keep biosimilars off the market.

Deallus Purchasing a Pipeline White Paper
DOWNLOAD WHITE PAPER

You may also be interested in…

  • HIV & AIDS Medication

HIV/AIDS

Human immunodeficiency virus (HIV) is the virus that is responsible for Acquired Immune Deficiency Syndrome (AIDS). HIV continues to be a major global public health issue having claimed the lives of 36.3 million people so far, according to World Health Organization (WHO).

  • Post-ASCO 2022- Summary of key breast cancer highlights

Post-ASCO 2022: Summary of key breast cancer highlights

With the conclusion of another ASCO, we were presented with exciting new breakthrough data of Antibody Drug Conjugates in breast cancer. Enhertu (trastuzumab deruxtecan) demonstrated significant benefit in the treatment of a new subtype of breast cancer, HR+/ /HER2-low.

BIO 2022: Biotechnology Innovation Organization (BIO) Convention

We’re excited to be attending The BIO International Convention. Jack Florio, Partner in Strategy Consulting at Deallus will be joining more than 3,000 delegates and exploring the latest innovation within the biotech space, as well as making the most of opportunities to meet and network with global thought leaders and industry peers.